Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

President Trump threatened 250% tariffs on pharma; Pfizer CEO contacted Trump about most favored nation pricing; Ex-X CEO joins eMed.

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

Ministers are preparing to boost NHS spending on US drugs in a race to avoid a future tariff hit from Donald Trump.

Pfizer CEO Albert Bourla said his company is in “very active discussions” over Trump’s request concerning most-favoured-nation pricing, according to news website FiercePharma. Bourla said he had ...

In May, Pfizer CEO Dr. Albert Bourla defended previous comments HHS officials made about mRNA vaccines. 2 At the time, he called mRNA vaccines the most utilized vaccines in human history. He cited the ...